Valeo Pharma (VPH) Q2 2024 earnings summary

Executive summary

• Q2 2024 delivered record revenues of CAD 14.1 million, up 4% year-over-year and sequentially, driven by strong growth in the respiratory and asthma franchises, with year-to-date revenues at CAD 27.7 million, also up 4% from the prior year period.

• Asthma franchise revenues, including Enerzair and Atectura, rose 52% year-over-year, with prescriptions up 96% for the 12 months ending April 30, 2024.

• Major restructuring of the respiratory commercial team was announced, reducing workforce by about 27 people (over 20%) and targeting annual savings of over CAD 5 million.

• The company remains focused on achieving EBITDA positive status by year-end 2024 and cash flow positivity thereafter.

Financial highlights

• Adjusted gross profit for Q2 2024 was CAD 3.4 million, down 27% from Q2 2023, mainly due to a reduced contribution from Xiidra.

• Net loss for Q2 2024 was CAD 7.8 million, a 21% increase from Q2 2023, impacted by lower gross profit and transformation costs of nearly CAD 500,000.

• Adjusted EBITDA loss for Q2 2024 was CAD 2.5 million, up 48% year-over-year.

• Operating expenses for Q2 2024 were CAD 6.8 million, down 2% year-over-year, with transformation costs included.

• Cash position at the end of Q2 2024 was CAD 6.9 million, a decrease of CAD 600,000 from year-end 2023.

Outlook and guidance

• Significant improvement in financial metrics is expected starting Q3 2024, with the full impact of cost savings in Q4.

• EBITDA breakeven is targeted for fiscal Q4 2024, with cash flow positivity to follow.

• Over CAD 7 million in cost savings are anticipated from restructuring and other measures.

• Management expects improving product mix and cost reduction measures to support a return to profitability in the second half of the year.